KYMR
Kymera Therapeutics, Inc. Common Stock
stockNASDAQ
kymera therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. we are advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform with a novel small molecule modality, our company is committed to accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. learn more at kymeratx.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 112.00 | 2026-09-28 | -4.18% | -2.641 |
| 1M | 117.39 | 2026-09-04 | -8.58% | -0.007 |
| 3M | 114.76 | 2026-07-06 | -6.48% | 0.531 |
| 6M | 85.27 | 2026-04-06 | +25.86% | 0.691 |
| 1Y | 57.55 | 2025-10-06 | +86.48% | 0.794 |
| 2Y | 43.06 | 2024-10-04 | +149.23% | — |
| 5Y | 61.47 | 2021-10-05 | +74.59% | 1.617 |
Kymera Therapeutics, Inc. Common Stock (NASDAQ:KYMR) stock price today is $107.32, and today's volume is 870,206. KYMR is down 2.543% today. The 30 day average volume is 730,961. KYMR market cap is $8.92B with 83.15M shares outstanding.